We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 334

Formulation patent allegations of non-infringement, obviousness and lack of utility justified

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 2 2015

Servier sought a prohibition order against Apotex in relation to its DIAMICRON MR gliclazide product. The application was dismissed. The patent at

Application for an order of prohibition is dismissed for a unit dose patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 23 2015

The Court found that Mylan’s allegations of lack of utility, anticipation and obviousness were justified. As a result, the application was dismissed

Application for an order of prohibition is dismissed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 23 2015

The Court found that Teva’s allegation of obviousness was justified. As a result, the application was dismissed

Other industry news: February 9 2015

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 9 2015

Health Canada has updated the Guidance Document: Patented Medicines (Notice of Compliance) Regulations

Finding of non-infringement upheld on appeal

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 9 2015

The Court of Appeal dismissed an appeal of a decision of the Court in a NOC proceeding finding that an allegation of non-infringement was justified

Appeal in NOC Proceeding dismissed as moot

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 9 2015

The Court of Appeal granted Teva’s motion to have an appeal from a NOC Proceeding dismissed as moot. The Respondent’s request for an oral hearing of

Order of prohibition granted in respect of use patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 26 2015

The Court found that Mylan’s allegations of lack of utility, and specifically lack of sound prediction, and obviousness-type double patenting were

Minister’s decision to grant NOA to generic company set aside, as the generic did not comply with the NOC regulations

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 19 2015

In this proceeding, Pfizer sought to judicially review the Minister of Health’s decision to grant Teva a NOC for exemestane. A company called GMP

Court refused to grant protective order covering NOA

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 19 2015

In the context of a proceeding brought pursuant to the NOC Regulations, Mylan sought a confidentiality that would allow it to designate portions of

Court finds claims do not cover method of medical treatment, orders that they issue

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 19 2015

In this decision, AbbVie brought a judicial review of a decision of the Commissioner of Patents refusing to issue its patent. The issue was whether